Nuclear pharmacy

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

Retrieved on: 
Tuesday, November 14, 2023
Acquisition, OTCQB, TLX, QSAM, FDA, Nuclear pharmacy, ASX, Orphan drug, Contingent value rights, Term sheet, Commercial property, Telix

Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.

Key Points: 
  • Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.
  • If the Acquisition does not close, the Collaboration Fee will be converted to Company common stock at a price of 6.70 per share.
  • Dr. C. Richard Piazza, QSAM’s Executive Chairman and co-Founder, stated, “We are thrilled to commence working with Telix by virtue of the Collaboration Fee to advance our technology and pursue a definitive agreement leading to the acquisition of QSAM by Telix.
  • With CycloSam® we plan to leverage Telix’s extensive experience and success in distributing short-life radiopharmaceuticals using a cold kit product from a nuclear pharmacy.

Nucleus RadioPharma Appoints Industry Veteran Mark Przekop as Chief Operating Officer to Lead Supply Chain Strategy

Retrieved on: 
Thursday, December 7, 2023
Biotechnology, Radiology, Health, Oncology, Nuclear pharmacy, Marketing, Patient, Cancer, PET, Multimedia, Knowledge, Nuclear medicine, Radiopharmaceutical

Nucleus RadioPharma , the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the expansion of its executive leadership team with Mark Przekop joining as Chief Operating Officer.

Key Points: 
  • Nucleus RadioPharma , the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the expansion of its executive leadership team with Mark Przekop joining as Chief Operating Officer.
  • As a veteran with over 35 years in the nuclear pharmacy and radiopharmaceuticals industry, Mark brings extensive commercial and operational experience in expanding supply chain networks, marketing and regulatory compliance oversight.
  • View the full release here: https://www.businesswire.com/news/home/20231207413093/en/
    “Mark’s experience and wealth of knowledge in business strategy, commercial manufacturing, and supply chain oversight in radiopharmaceuticals, as demonstrated by his impressive background in nuclear medicine is a perfect fit for us,” said Charles S. Conroy, CEO of Nucleus RadioPharma.
  • Please visit https://nucleusrad.com/#about for more information and to learn more about Nucleus RadioPharma’s partnering opportunities.

RADIOPHARMACY NETWORK RLS APPOINTS MATT MOLCHAN AS SENIOR VICE PRESIDENT OF BUSINESS DEVELOPMENT

Retrieved on: 
Tuesday, September 5, 2023
Business development, Air force academy, University, Senior, Clinical trial, PET, MBA, United States Air Force Academy, Economics, Nuclear medicine, CDMO, RLS, Nuclear pharmacy, Development, Health, Management

LAKE ZURICH, Ill., Sept. 5, 2023 /PRNewswire/ -- Today, RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear pharmacy network in the US, announced the appointment of industry veteran Matt Molchan as Senior Vice President of Business Development. With over two decades of experience in nuclear medicine and healthcare, Molchan will play a key role in driving new business growth as RLS continues to scale and expand into new areas, ranging from clinical trials and CDMO work to PET and patient dose distribution.

Key Points: 
  • LAKE ZURICH, Ill., Sept. 5, 2023 /PRNewswire/ -- Today, RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear pharmacy network in the US, announced the appointment of industry veteran Matt Molchan as Senior Vice President of Business Development.
  • "With a proven track record in nuclear medicine, Matt will help to unlock the next phase of business growth for RLS.
  • As Senior Vice President of Business Development, Molchan will lead business development strategy and execution for RLS, identifying new opportunities as the radiopharmacy network expands.
  • His role will include setting national, regional and local business development strategy across the RLS network, which includes 31 radiopharmacies across 18 states in top markets nationwide.

RLS APPOINTS GLENN SULLIVAN AS DIRECTOR OF REGULATORY AFFAIRS

Retrieved on: 
Tuesday, June 13, 2023
Sullivan, Joint Commission, Mathematics, Lurie Children's Hospital, California InterContinental University, American InterContinental University, PET, MBA, Research, Radiopharmaceutical, Organization, Nuclear medicine, Cardinal Health, Wittenberg University, Business administration, Medical Center, National Louis University, RLS, Nuclear pharmacy, Hospital, Regulatory affairs, Development, Health, Medical device

LAKE ZURICH, Ill., June 13, 2023 /PRNewswire/ -- Today, RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear pharmacy network in the US, announced the appointment of Glenn Sullivan as Director of Regulatory Affairs. Sullivan, a 25-year veteran of the radiopharmacy and healthcare industry, will help ensure RLS continues to meet the highest bar for regulatory compliance on the local, state and federal levels as the radiopharmacy network continues to expand.

Key Points: 
  • LAKE ZURICH, Ill., June 13, 2023 /PRNewswire/ -- Today, RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear pharmacy network in the US, announced the appointment of Glenn Sullivan as Director of Regulatory Affairs.
  • "Glenn's appointment as Director of Regulatory Affairs marks an exciting new chapter for RLS as we continue to scale for long-term, sustainable growth," said Stephen Belcher, CEO of RLS.
  • As Director of Regulatory Affairs, Sullivan will drive local, state and federal regulatory strategy for the company, ensuring RLS continues to meet the highest standards in regulatory compliance as the only Joint Commission accredited radiopharmacy network in the country.
  • Sullivan brings over 25 years of experience in regulatory affairs, quality and compliance with a strong focus in the nuclear sector.

SpectronRx and RLS Team Up to Give the Radiopharmaceutical Pipeline and Supply Chain a Much-Needed Boost

Retrieved on: 
Wednesday, June 7, 2023
Partnership, Drug development, ISO, Radiopharmaceutical, Cancer, Research, EMA, Nuclear medicine, Patient, QA, Medicine, RLS, Quality control, Nuclear pharmacy, FDA, Health, Actinium-225, Safety, Medical imaging

INDIANAPOLIS and LAKE ZURICH, Ill., June 7, 2023 /PRNewswire/ -- SpectronRx, a leading radiopharmaceutical developer and manufacturer, and RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the US, today announced an agreement that will significantly enhance the supply and availability of diagnostic and therapeutic radiopharmaceuticals. With this collaboration, both companies hope to further bridge the gap between drug development, manufacturing, distribution and patient care by improving production and increasing the availability of life-saving medicines. 

Key Points: 
  • "Radiopharmaceuticals are essential to diagnosing and treating diseases ranging from cancer to neurodegenerative disorders," said SpectronRx CEO John Zehner.
  • As part of the agreement, SpectronRx will manufacture radiopharmaceutical products for RLS and other partners, and RLS will distribute them.
  • "Critical for patient care, some of the most effective radiopharmaceutical treatments are in limited supply," said SpectronRx President Anwer Rizvi.
  • SpectronRx has three distinct specialties: Radiopharmaceutical Contract Development (rCDMO), Radiopharmaceutical Contract Manufacturing (rCMO), and Isotope Production.

QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center

Retrieved on: 
Tuesday, May 23, 2023
Partnership, Bone, Cancer, Osteosarcoma, OTCQB, Breast, Prostate, MD, Patient, Sarcoma, Medical Center, RLS, Nuclear pharmacy, QSAM, Medical imaging, Pharmaceutical industry

QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in patients, as well as assess early efficacy signals. Patients with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as patients with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults -- may be eligible.

Key Points: 
  • QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in patients, as well as assess early efficacy signals.
  • Patients with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as patients with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults -- may be eligible.
  • "We are pleased to be working with the excellent team at Insight Hospital and Medical Center to continue the expansion of our drug development program for CycloSam® in the large population center of Chicago,” stated Douglas R. Baum, CEO and co-founder of QSAM.
  • “Therapeutic radiopharmaceuticals like CycloSam® represent a novel and potentially important treatment option for patients suffering from this debilitating and deadly disease.”

Philochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements

Retrieved on: 
Tuesday, December 13, 2022
Molecule, Isotopia Festival, Therapy, Heterotrimeric G protein, Precision medicine, Cytokine, Business, Jaden Philogene-Bidace, Doctor of Philosophy, Nuclear pharmacy, Small molecule, Patient, Isotope, GMP, Disease, Neoplasm, CMO, Antibody, Molecular imaging, FAP, Radiopharmaceutical, Business development, Medical imaging, Pharmaceutical industry, Mercury

OTELFINGEN, Switzerland, SEIBERSDORF, Austria and PETAH TIKVA, Israel, Dec. 13, 2022 /PRNewswire/ -- Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have today announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

Key Points: 
  • Under these agreements, Isotopia will supply high quality 177 Lu-n.c.a to Seibersdorf Laboratories for the purpose of conducting development and manufacturing activities for Philochem's proprietary therapeutic candidate, OncoFAP-23.
  • Sammuele Cazzamalli, PhD, Head of Small Molecule Therapeutics at Philochem commented: " We are delighted to start working with Isotopia and Seibersdorf Laboratories on the manufacturing of our Targeted Radioligand Therapeutics.
  • The experienced Isotopia team, together with its nuclear pharmacy, cyclotron facility, 177Lu production site and sterile manufacturing plant, are a well-established platform for manufacturing and collaborations.
  • Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Isotope, Half-life, Peptide, Nuclear pharmacy, Database administrator, Therapy, Safety, Radiation, Molecular imaging, Clovis Oncology, Sarcoma, FDA, FAP, SNMMI, Neoplasm, Antibody, Company, Population, Cancer, Private Securities Litigation Reform Act, Isotopia Festival, EANM, U.S. Securities and Exchange Commission, Program, Patient, Colon, CEO, Oncology, Gallium, Cell, Fibroblast, Radionuclide, NCT, NASDAQ, CAFS, Research, Security (finance), Congress, Mesothelioma, BD, GMP, EMA, View, Drug discovery, TRT, Pharmaceutical industry, Medical imaging

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement further secures our ability to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.
  • Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security, said Keren Moshkoviz, Deputy CEO and BD at Isotopia.

ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network

Retrieved on: 
Thursday, September 8, 2022
Neoplasm, Molecular imaging, Patient, CEO, Cancer, Radionuclide, Artificial intelligence, Radiation, Health, Diagnosis, BAMF, Radiopharmaceutical, Quality of life, Nuclear medicine, ITM, Organization, Molecule, Nuclear pharmacy, Therapy, III, Garching (Munich U-Bahn), Medical imaging

The leading state-of-the-art facility of BAMF's theranostic network opened this month in Grand Rapids, Michigan.

Key Points: 
  • The leading state-of-the-art facility of BAMF's theranostic network opened this month in Grand Rapids, Michigan.
  • ITM will contribute its deep understanding of the development, production and global supply of its high-quality diagnostic and therapeutic radioisotopes.
  • BAMF Health is achieving Intelligence-Based Precision Medicine through Artificial Intelligence enabled Molecular Imaging and Molecular Targeted Radiation Therapy.
  • The location includes the worlds most advanced cyclotron-equipped Radiopharmacy, Molecular Imaging Clinic, and Theranostic (Molecular Therapy) Clinic.

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development

Retrieved on: 
Monday, July 25, 2022
Nuclear physics, SL, Psychiatry, Monkeypox, Infection, CNS, Company, Security (finance), Smallpox, Running, Translational research, Prader–Willi syndrome, Research, U.S. Securities and Exchange Commission, Cancer, University, Cocaine, Pain, Neurology, IND, Long COVID, GLOBE, Fibromyalgia, Industry, SEC, Government, Disease, RDC, Hydrogen chloride, Failure, COVID-19, Pharmacy, Achievement, Central nervous system, Nuclear pharmacy, Autoimmunity, FDA, Nebraska Medicine, CD154, University of Nebraska Medical Center, Nasdaq, Therapy, Annual report, Risk, Vaccine, Bavari, Private Securities Litigation Reform Act, USAMRIID, Leadership, United States Army Research Institute of Environmental Medicine, Investigational New Drug, Education Development Center, Degenerative disease, Pharmaceutical industry, Tonix Pharmaceuticals, Immunology

CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development.

Key Points: 
  • CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development.
  • and, as part of his role, will oversee scientific development at Tonixs Infectious Disease R&D Center located there.
  • We are delighted that Dr. Bavari has joined our team to lead our infectious disease research and development efforts, said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals.
  • I am excited to join Tonix and to lead the Company's efforts in infectious disease research and development programs, including vaccines in development for monkeypox, smallpox and COVID-19, said Dr. Bavari.